Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2019

View Archived Issues

Crystal structures may provide crystal ball for anti-TB drugs

Trial results reported for ublituximab, umbralisib and ibrutinib combination in B-cell malignancies

Resistin promotes VEGF-A expression and angiogenesis in chondrosarcoma through inhibition of a miRNA

Sylentis presents results from phase III HELIX study of tivanisiran

Bayer and Kyoto University form new research alliance in pulmonology

Veru initiates phase Ib/II study of VERU-111 in advanced mCRPC

Vanderbilt University describes muscarinic acetylcholine M4 receptor antagonists

New 5-HT-2A antagonists idenified at Tonix Pharmaceuticals

Syros Pharmaceuticals describes TAM receptor tyrosine kinase inhibitors

Ohio State University, Brigham and Women's Hospital patent SLC1A2 activators

Innate Tumor Immunity presents NACHT, LRR and PYD domains-containing protein 3 agonists

New bromodomain-containing protein 4 inhibitors reported by Zhejiang Hisun Pharmaceutical

Metrion Biosciences and LifeArc to collaborate on ion channel drug discovery project

Phase I results for LMB-100 plus nab-paclitaxel in pancreatic adenocarcinoma

Invenra, Wisconsin Alumni Research Foundation enter neuroblastoma collaboration

VEE TC-83 vaccine demonstrates safety in phase II study

Nanobiotix presents clinical data for NBTXR-3 in patients with HCC and liver metastasis

Theravance Biopharma presents novel dual AT1 antagonist/NEP inhibitor, TD-0212

Lacosamide shows promise in patients with Nav1.7-related small fiber neuropathy

Ipafricept found safe in patients with stage IV pancreatic cancer

MeiraGTx and Janssen collaborate on gene therapies for inherited retinal diseases

New pilot study of donor CMV-specific CTLs to treat CMV infection in transplant patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...